Study wrapper · #1045
Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
Gibble TH, Leith A, Harrison L, et al. Obesity pillars. 2026.
DOI: 10.1016/j.obpill.2026.100300PubMed: 42491427
Editor's note
This is a cross-sectional survey capturing self-reported satisfaction and prescribing experience with tirzepatide, not a controlled outcomes study. Satisfaction data are inherently subjective and vulnerable to selection and reporting biases, and the analysis was industry-relevant secondary survey data. It usefully describes real-world experience with tirzepatide while carrying limited weight as evidence of clinical benefit.
Plain-language abstract
This real-world survey of 151 physicians and 199 people with obesity but without type 2 diabetes found high reported satisfaction, adherence, and willingness to recommend once-weekly tirzepatide. The findings reflect self-reported experience and satisfaction rather than measured clinical outcomes.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Weak / none
Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway.
Tissue & celln=——2026
Mixed
Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study.
Obesity pillarsn=——2026